Toolbox COVID-19

Key
Resources
Clinical
Guidelines
Women & Child
Health
Pharmacy &
Technologies
Public
Health
Capacity
Building
COUNTRIES
TOOLBOXES
- Conflict
- Zika
- TB
- Cholera
- HIV
- Polio
- Rapid Response
- Refugee
- Disability
- Specific Hazards
- Social Ethics
- Health Financing Toolbox

Middle East and North Africa
West and Central Africa
East and Southern Africa
South–East Asia Region
Western Pacific Region
Eastern Europe and Central Asia
Latin America and the Carribbean
Western and Central Europe
North America
South Sudan
Turkmenistan
Jamaica
Japan
Belgium
France
Maldives
Mauritius
Tunisia
Portugal
Spain
South Korea
Algeria
Azerbaijan
Belarus
French Guyana
Israel

Login
Register
English

COVID-19

TOOLBOX

Suggest new resources

COVID-19
Vaccine Candidates & Research
Vaxzevria (Astra Zeneca)

Filter

Featured

Recommendations

Language

English

French

Portuguese

German

Russian

Arabic

Chinese

Document type

Fact sheets

Guidelines

Studies & Reports

Manuals

Situation Updates

Countries / Regions

India

East and Southern Africa

West and Central Africa

South Sudan

Germany

Brazil

Western and Central Europe

South Korea

Authors & Publishers

World Health Organization WHO

Africa CDC Centres for Disease Control and Prevention

African Union

European Medicines Agency EMA

World Health Organization WHO, et al.

and C. Wonodi

BBC

Gesellschaft für Thrombose-undHämostaseforschung e.V. GTH

Greinacher, A., et al.

Knoll, M.D.

Medicines and Healthcare products Regulatory Agency (MHRA) UK

OPAS

OPAS, OMS

Pan American Health Organisation PAHO

Vygen-Bonnet S, Koch J, Bogdan C, et al.

World Health Organization WHO, Regional Office of Europe

World Health Organization WHO, SAGE

Publication Years

2020-2026

AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine

World Health Organization WHO (2021) C_WHO

10 May 2021. Manufactureres: SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])] Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)] The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto ... r vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks. more

Download

View PDF

Add to my

Documento de referência sobre a vacina AZD1222 contra COVID-19 desenvolvida pela Universidade de Oxford e pela AstraZeneca, 1 de março de 2021

Pan American Health Organisation PAHO (2021) C_WHO

Este documento de referência foi preparado pelo Grupo de Trabalho sobre Vacinas contra COVID-19 do Grupo Consultivo Estratégico de Especialistas em Imunização (SAGE) para orientar as discussões do SAGE em sua reunião extraordinária de 8 de fevereiro de 2021, que resultou na publicação do do ... cumento da OMS de 10 de fevereiro de 2021 Recomendações provisórias para o uso da vacina AZD1222 [ChAdOx1-S (recombinante)] contra COVID-19 desenvolvida pela Universidade de Oxford e pela AstraZeneca. Os dois documentos estão disponíveis na página sobre COVID-19 do SAGE: https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/covid-19-materials. Têm sido usados vetores de adenovírus deficientes na replicação contendo um transgene específico do patógeno como novas vacinas devido à sua capacidade de induzir respostas humorais e celulares fortes. more

Download

View PDF

Add to my

Recommandations provisoires concernant l’utilisation du vaccin ChAdOx1-S [‎recombinant]‎ contre la COVID-19 (‎vaccin anti-COVID-19 AZD1222 Vaxzevria™ d’AstraZeneca, COVISHIELD™ de SII)‎
recommended

World Health Organization WHO (2021) C_WHO

orientations provisoires, première publication: 10 février 2021, mise à jour : 21 avril 2021, dernière mise à jour : 30 juillet 2021

Download

View PDF

Add to my

Предварительные рекомендации по применению вакцины ChAdOx1-S [‎рекомбинантной]‎ против COVID-19 (‎вакцина AstraZeneca COVID-19 AZD1222, Vaxzevria™, SII COVISHIELD™)
recommended

World Health Organization WHO (2021) C_WHO

временное руководство. Первый выпуск: 10 февраля 2021 г. Обновлено: 21 апреля 2021 г. Последнее обновление 30 июля 2021г.

Download

View PDF

Add to my

Recomendações provisórias para o uso da vacina ChAdOx1-S [recombinante] contra COVID-19 (vacina AstraZeneca COVID-19 AZD1222 Vaxzevria™, SII COVISHIELD™) - Última atualização em 30 de julho de 2021

OPAS, OMS OPAS (2021) CC

Interim recommendations for the use of ChAdOx1-S [recombinant] COVID-19 vaccine (AstraZeneca COVID-19 AZD1222 Vaxzevria™, SII COVISHIELD™ vaccine) - Last updated 30 July 2021

External Link

Add to my

Coronavirus: India approves vaccines from Bharat Biotech and Oxford/AstraZeneca

BBC (2020) CC

Create your own
Login

Home
Contact
Data privacy
Legal notice
FAQ
About
Sitemap

A Project by

medbox @ 2026

AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine

Documento de referência sobre a vacina AZD1222 contra COVID-19 desenvolvida pela Universidade de Oxford e pela AstraZeneca, 1 de março de 2021

Recommandations provisoires concernant l’utilisation du vaccin ChAdOx1-S [‎recombinant]‎ contre la COVID-19 (‎vaccin anti-COVID-19 AZD1222 Vaxzevria™ d’AstraZeneca, COVISHIELD™ de SII)‎ recommended

Предварительные рекомендации по применению вакцины ChAdOx1-S [‎рекомбинантной]‎ против COVID-19 (‎вакцина AstraZeneca COVID-19 AZD1222, Vaxzevria™, SII COVISHIELD™) recommended

Recomendações provisórias para o uso da vacina ChAdOx1-S [recombinante] contra COVID-19 (vacina AstraZeneca COVID-19 AZD1222 Vaxzevria™, SII COVISHIELD™) - Última atualização em 30 de julho de 2021

Coronavirus: India approves vaccines from Bharat Biotech and Oxford/AstraZeneca

Recommandations provisoires concernant l’utilisation du vaccin ChAdOx1-S [‎recombinant]‎ contre la COVID-19 (‎vaccin anti-COVID-19 AZD1222 Vaxzevria™ d’AstraZeneca, COVISHIELD™ de SII)‎
recommended

Предварительные рекомендации по применению вакцины ChAdOx1-S [‎рекомбинантной]‎ против COVID-19 (‎вакцина AstraZeneca COVID-19 AZD1222, Vaxzevria™, SII COVISHIELD™)
recommended